ACRS

3.4401.71%
RK

Roland Kolbeck

Chief Scientific Officer

Dr. Roland Kolbeck, Ph.D. is Chief Scientific Officer of Aclaris Therapeutics, Inc. from July 2025. His extensive experience in areas including inflammation and antibody development be important as Company develops its growing portfolio of immuno-inflammatory product candidates, including its next generation kinase and cytokine signaling pathway inhibitors and potential first-in-class bispecific antibodies. He brings nearly three decades of senior R&D leadership in small and large biopharmaceutical companies and a proven track record of successful drug development to Aclaris. He joins the team from Spirovant Sciences, where he served as Chief Scientific Officer and directed company's strategy related to new indications, targets and investments. Previously, he was Vice President, Head of Respiratory, Inflammation and Autoimmune Research (RIA) at MedImmune, AstraZeneca's global biologics organization, where he provided strategic direction as Chair of the RIA Research Committee and as a member of the Research Leadership Team and Early-Stage Portfolio Committee. Six monoclonal antibodies originating from the RIA portfolio have since been approved by the FDA. Prior to Medimmune, he served in senior scientific roles at Peptimmune and Millennium Pharmaceuticals. He has published over 100 peer-reviewed articles in scientific journals such as Nature, Immunity and New England Journal of Medicine. He earned his M.S. and Ph.D. at the University of Regensburg and Max Planck Institute for Neurobiology (now the Max Planck Institute for Biological Intelligence), in Munich, Germany.

Positions